Change search
ReferencesLink to record
Permanent link

Direct link
Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
GlaxoSmithKline, DDW, Med Dev Campus,Severo Ochoa 2, Madrid 28760, Spain..
GlaxoSmithKline, DDW, Med Dev Campus,Severo Ochoa 2, Madrid 28760, Spain..
GlaxoSmithKline, DDW, Med Dev Campus,Severo Ochoa 2, Madrid 28760, Spain..
Show others and affiliations
2016 (English)In: European Journal of Pharmaceutical Sciences, ISSN 0928-0987, E-ISSN 1879-0720, Vol. 93, 319-333 p.Article in journal (Refereed) Published
Abstract [en]

The current first-line therapy for drug-susceptible tuberculosis consists of rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (EMB). In this study, we determined the population pharmacokinetics (PopPK) of RIF, INH, EMB and PZA using original experimental sampling designs for single-dose intravenous (IV) and single- and multiple-dose oral administration studies in the mouse model, and used these PopPK models to develop and evaluate new, more informative sampling designs with the aim of reducing the number of animals required for each drug. The RIF, INH, EMB and PZA blood concentrations after single oral and IV doses and multiple-dose oral administrations based on the original designs were used in the PopPK analysis using NONMEM software. The final PopPK models described the data well, Stochastic simulation and estimation were used to optimise the designs. The relative bias and relative imprecision of each pharmacokinetic parameter for each drug were derived and assessed to choose the final designs. The final single-dose IV and oral designs included up to eight samples per mouse with a total of 24 mice required for RIF and EMB and 33 mice for INH and PZA. In the new multiple-dose (zipper) oral designs, the mice were divided into two groups of three per dose, and four samples were taken from each mouse to cover all seven or eight sampling time points. The final number of mice required for the multiple-dose oral designs was 30 for RIF, INH and EMB, 36 for PZA. The number of mice required in the new designs for RIF, INH and EMB was decreased by up to 7-fold and the relative bias and relative imprecision in the parameter estimates were at least similar to those in the original designs.

Place, publisher, year, edition, pages
2016. Vol. 93, 319-333 p.
Keyword [en]
Pharmacoldnetics, Design, Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
National Category
Pharmaceutical Sciences
URN: urn:nbn:se:uu:diva-307268DOI: 10.1016/j.ejps.2016.07.017ISI: 000384853200034PubMedID: 27473307OAI: diva2:1046408
Swedish Research CouncilEU, European Research CouncilGlaxoSmithKline (GSK)
Available from: 2016-11-14 Created: 2016-11-11 Last updated: 2016-11-14Bibliographically approved

Open Access in DiVA

fulltext(2177 kB)42 downloads
File information
File name FULLTEXT01.pdfFile size 2177 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Chen, ChunliSimonsson, Ulrika S. H.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
European Journal of Pharmaceutical Sciences
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 42 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 109 hits
ReferencesLink to record
Permanent link

Direct link